Blake J Cochran1, Kwok-Leung Ong1, Bikash Manandhar1, Kerry-Anne Rye2. 1. Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Sydney, Level 4E Wallace Wurth Building, Kensington, New South Wales, 2052, Australia. 2. Lipid Research Group, School of Medical Sciences, Faculty of Medicine, University of New South Wales Sydney, Level 4E Wallace Wurth Building, Kensington, New South Wales, 2052, Australia. k.rye@unsw.edu.au.
Abstract
PURPOSE OF THE REVIEW: Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states. RECENT FINDINGS: Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1. APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.
PURPOSE OF THE REVIEW: Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states. RECENT FINDINGS: Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1. APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.
Authors: Patrick Kee; Kerry-Anne Rye; John L Taylor; P Hugh R Barrett; Philip J Barter Journal: Arterioscler Thromb Vasc Biol Date: 2002-11-01 Impact factor: 8.311
Authors: Ryan E Moore; Mohamad Navab; John S Millar; Francesca Zimetti; Susan Hama; George H Rothblat; Daniel J Rader Journal: Circ Res Date: 2005-09-08 Impact factor: 17.367
Authors: Robert S Rosenson; H Bryan Brewer; W Sean Davidson; Zahi A Fayad; Valentin Fuster; James Goldstein; Marc Hellerstein; Xian-Cheng Jiang; Michael C Phillips; Daniel J Rader; Alan T Remaley; George H Rothblat; Alan R Tall; Laurent Yvan-Charvet Journal: Circulation Date: 2012-04-17 Impact factor: 29.690
Authors: A Michael Lincoff; Stephen J Nicholls; Jeffrey S Riesmeyer; Philip J Barter; H Bryan Brewer; Keith A A Fox; C Michael Gibson; Christopher Granger; Venu Menon; Gilles Montalescot; Daniel Rader; Alan R Tall; Ellen McErlean; Kathy Wolski; Giacomo Ruotolo; Burkhard Vangerow; Govinda Weerakkody; Shaun G Goodman; Diego Conde; Darren K McGuire; Jose C Nicolau; Jose L Leiva-Pons; Yves Pesant; Weimin Li; David Kandath; Simon Kouz; Naeem Tahirkheli; Denise Mason; Steven E Nissen Journal: N Engl J Med Date: 2017-05-18 Impact factor: 91.245
Authors: Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer Journal: N Engl J Med Date: 2007-11-05 Impact factor: 91.245
Authors: Gregory G Schwartz; Anders G Olsson; Markus Abt; Christie M Ballantyne; Philip J Barter; Jochen Brumm; Bernard R Chaitman; Ingar M Holme; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Hardi Mundl; Stephen J Nicholls; Prediman K Shah; Jean-Claude Tardif; R Scott Wright Journal: N Engl J Med Date: 2012-11-05 Impact factor: 91.245
Authors: Sophia Metz; Nikolaj T Krarup; Thomas Bryrup; Julie Støy; Ehm A Andersson; Christina Christoffersen; Matt J Neville; Malene R Christiansen; Anna E Jonsson; Daniel R Witte; Ulla Kampmann; Lars B Nielsen; Niklas R Jørgensen; Fredrik Karpe; Niels Grarup; Oluf Pedersen; Tuomas O Kilpeläinen; Torben Hansen Journal: J Endocr Soc Date: 2022-03-04